SAN CARLOS, Calif., July 29 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has enrolled the first subject in a single-center, Phase 1 trial of recombinant, secreted protein, NU206, the company's lead compound from its Wnt Therapeutics Program. This double-blind, placebo-controlled, single-ascending dose (SAD) trial will determine the safety, tolerance and pharmacokinetics of a single intravenous (IV) administration of NU206, in approximately 48 healthy male volunteers. Participants will be enrolled in up to six cohorts of varying doses, with a maximum dose of 0.80 mg/kg.
"The initiation of this healthy volunteer trial, coupled with the Phase 1b multiple-ascending dose study that will start later this year or early next year, allows us to accelerate NU206 development," said Dr. Ted W. Love, chairman and chief executive officer of Nuvelo. "Due to its ability to promote cell growth and repair in preclinical studies, we believe NU206 has the potential to offer a novel approach for the treatment of serious medical conditions including gastrointestinal (GI) injury, inflammatory bowel disease and bone disease. The two healthy volunteer trials will provide useful insight for the multiple indications that we plan to investigate with NU206."
NU206 (R-spondin1) is a recombinant, secreted protein that acts as a
key regulator of the Wnt pathway, the critical pathway that stimulates cell
growth and differentiation during homeostasis and pathogenesis in specific
tissues including the GI epithelium and bone. Preclinical studies suggest
it can promote growth and repair in animal models of radiation or cancer
chemotherapy induced GI injury, inflammatory bowel disease, bone disease
and wound he
|SOURCE Nuvelo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved